Screening of common genomic biomarkers to explore common drugs for the treatment of pancreatic and kidney cancers with type-2 diabetes through bioinformatics analysis

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 2, 2025

Type 2 diabetes (T2D) is a crucial risk factor for both pancreatic cancer (PC) and kidney (KC). However, effective common drugs treating PC and/or KC patients who are also suffering from T2D currently lacking, despite the probability of their co-occurrence. Taking disease-specific multiple during co-existence diseases may lead to adverse side effects or toxicity due drug-drug interactions. This study aimed identify T2D-, KC-causing genomic biomarkers (cGBs) highlighting pathogenetic mechanisms explore as treatment. We analyzed transcriptomic profile datasets, applying weighted gene co-expression network analysis (WGCNA) protein-protein interaction (PPI) approaches PC-, cGBs. then disclosed through ontology (GO) terms, KEGG pathways, regulatory networks, DNA methylation these Initially, we identified 78 differentially expressed genes (cDEGs) that could distinguish T2D, PC, samples controls based on profiles. From these, six top-ranked cDEGs (TOP2A, BIRC5, RRM2, ALB, MUC1, E2F7) were selected cGBs considered targets exploring drug molecules each three diseases. Functional enrichment analyses, including GO analyses involving transcription factors (TFs) microRNAs, along with immune infiltration studies, revealed critical molecular linked KC, T2D. Finally, (NVP.BHG712, Irinotecan, Olaparib, Imatinib, RG-4733, Linsitinib) potential treatments co-existence, supported by literature reviews. Thus, this bioinformatics provides valuable insights resources developing genome-guided treatment strategy

Language: Английский

Exploring common genomic biomarkers to disclose common drugs for the treatment of colorectal cancer and hepatocellular carcinoma with type-2 diabetes through transcriptomics analysis

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0319028 - e0319028

Published: March 24, 2025

Type 2 diabetes (T2D) is a crucial risk factor for both colorectal cancer (CRC) and hepatocellular carcinoma (HCC). However, so far, there was no study that has investigated common drugs against HCC CRC during their co-occurrence with T2D patients. Consequently, patients often require multiple disease-specific drugs, which can lead toxicities adverse effects to the due drug-drug interactions. This aimed identify genomic biomarkers (cGBs) associated pathogenetic mechanisms underlying CRC, HCC, uncover potential therapeutic compounds these three diseases. Firstly, we identified 86 differentially expressed genes (cDEGs) capable of separating each from control groups based on transcriptomic profiling. Of cDEGs, 37 were upregulated 49 downregulated. Genetic association studies average Log2 fold-change (aLog2FC) cDEGs suggested genetic among T2D. Subsequently, six top-ranked (MYC, MMP9, THBS1, IL6, CXCL1, SPP1) as through protein-protein interaction (PPI) network analysis. Further analysis cGBs GO-terms KEGG pathways revealed shared diseases, including specific biological processes, molecular functions, cellular components signaling pathways. The gene co-regulatory two transcription factors (FOXC1 GATA2) miRNAs (hsa-mir-195-5p, hsa-mir-124a-3p, hsa-mir-34a-5p) transcriptional post-transcriptional regulators cGBs. Finally, cGBs-guided seven candidate (Digitoxin, Camptosar, AMG-900, Imatinib, Irinotecan, Midostaurin, Linsitinib) treatment T2D, docking, cross-validation, ADME/T (Absorption–Distribution–Metabolism–Excretion–Toxicity) Most findings received support by literature review diseases individual studies. Thus, this offers valuable insights researchers clinicians improve diagnosis and/or

Language: Английский